Aton Announces It Will Be Attending Egyptian Mining Day At PDAC

Aton Announces It Will Be Attending Egyptian Mining Day At PDAC

VANCOUVER, British Columbia, Feb. 18, 2020 (GLOBE NEWSWIRE) — Aton Resources Inc. (AAN: TSX-V) (“Aton” or the “Company”) is pleased to announce that it will be attending Egyptian Mining Day on March 1, 2020 at the Prospectors & Developers Association of Canada’s (PDAC) annual convention.
About Aton Resources Inc.Aton Resources Inc. (AAN: TSX-V) is focused on its 100% owned Abu Marawat Concession (“Abu Marawat”), located in Egypt’s Arabian-Nubian Shield, approximately 200 km north of Centamin’s world-class Sukari gold mine. Aton has identified numerous gold and base metal exploration targets at Abu Marawat, including the Hamama deposit in the west, the Abu Marawat deposit in the northeast, and the advanced Rodruin exploration prospect in the south of the Concession. Three historic British mines are also located on the Concession at Sir Bakis, Semna and Abu Garida. Aton has identified several distinct geological trends within Abu Marawat, which display potential for the development of a variety of styles of precious and base metal mineralisation. Abu Marawat is over 596 km2 in size and is located in an area of excellent infrastructure; a four-lane highway, a 220kV power line, and a water pipeline are in close proximity, as are the international airports at Hurghada and Luxor.For further information regarding Aton Resources Inc., please visit us at www.atonresources.com or contact:Note Regarding Forward-Looking StatementsSome of the statements contained in this release are forward-looking statements. Since forward-looking statements address future events and conditions; by their very nature they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.
CBJ Newsmakers

Recommended
La filiale d'AgraFlora, Farmako GmbH, obtient une licence spéciale autorisant la vente de cannabis médical traité par irradiationRevive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis